A research team from the Department of Pharmacology and Pharmacy at the LKS Faculty of Medicine of the University of Hong Kong (HKUMed) has developed an innovative AI-based cardiovascular risk prediction tool, called CardiOmicScore
A research team led by Professor Jaehyuk Cho from the Department of Software Engineering at Jeonbuk National University in South Korea, have developed an innovative model, named BiT-MAML, aimed at tackling inter-patient variability in BG prediction.
Philips (NYSE: PHG)+ announced today that it received FDA 510(k) clearance for its SmartHeart planning solution.
A machine-learning model developed by Weill Cornell Medicine investigators may provide clinicians with an early warning of a complication that can occur late in pregnancy.
A team of researchers from Taiwan has developed PanMETAI, an AI-powered platform that analyzes metabolic fingerprints in a simple blood sample to detect pancreatic cancer at its earliest stages—when treatment is most effective—achieving up to 94% diagnostic accuracy.
A new tool co-developed by investigators from Cedars-Sinai Health Sciences University can predict which of two available chemotherapy options for pancreatic cancer would be more effective for an individual patient.
Researchers at the Johns Hopkins Kimmel Cancer Center report that an artificial intelligence (AI)-based liquid biopsy test using genome-wide cell-free DNA (cfDNA) fragmentation patterns and repeat landscapes can detect early liver fibrosis and cirrhosis.
TORONTO and DALLAS, March 3, 2026 /PRNewswire/ – Perimeter Medical Imaging AI, Inc. (TSXV: PINK) (OTCQX: PYNKF) (“Perimeter” or the “Company”), a commercial-stage medical technology company, announced today that it has received U.S. Food and Drug Administration (“FDA”) premarket approval (“PMA”) for Claire™ (formerly the Perimeter OCT B-Series with ImgAssist AI 2.0), the first AI-enabled imaging device approved in the United States for intraoperative breast cancer margin assessment.
A new, fully customizable 3D printed socket design is set to transform the prosthetics industry.
STOCKHOLM, March 2, 2026 /PRNewswire/ — SciBase Holding AB (“SciBase”) (STO: SCIB), a leading developer of AI-based diagnostic solutions for skin disorders, today announced that it has received approval by FDA for its supplement to extend the labelling to include other healthcare professionals and not only dermatologists to perform the Nevisense procedure